Stay updated with breaking news from Capricor Stealth. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Chris Wack Capricor Therapeutics shares were up 7% at $4.42 after the company said its proprietary StealthX exosome-based multivalent vaccine for the...
Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO,…
-24-Month Open Label Extension Data from HOPE-2 Study Supports CAP-1002’s Sustained Efficacy and Safety in Treating Duchenne Muscular Dystrophy--C...